Sotyktu (deucravacitinib) long-term data demonstrate durable efficacy and consistent safety for up to three years in moderate-to-severe plaque psoriasis – BMS
Bristol Myers Squibb announced new three-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. At Week… read more.
